Why do you need this?
Your individual NPI number is required to verify that you are a health care provider.

 Log In or Register

Log In
 Close
* = Required field


Remember my e-mail address
Log In Forgot Password?
Not Registered?
AZ GatewayAZ Connect
Close
Find My Representative
Find your Personal Account Specialist, who can answer questions and provide information about NEXIUM® (esomeprazole magnesium). Fill out the fields below to get started.



Find Representative
OR
Call Me Now
Sorry, there are no Personal Account Specialists currently available.

If you would like information regarding products from AstraZeneca, please call 1-888-692-9737, during our normal business hours Monday through Friday, 8:30 am to 8:30 pm ET, excluding holidays.
AZ GatewayAZ Connect
Close
AZ TouchPoints News
The AZ TouchPoints Web site gives you direct access to AstraZeneca services and support. Here, you can easily find online sample ordering, formulary information, and patient education materials for select AstraZeneca medicines. Go to About AZ TouchPoints
AstraZeneca Professional Sites
To learn more about AstraZeneca medicines, visit the AZ corporate site for a complete list of professional Web sites.
Go to Web site directory
AstraZeneca Medical Affairs
Visit the AstraZeneca medical affairs Web site to get answers to questions about AZ products and medicines.
Go to AZ US Medical Information

Commercial Coverage

NEXIUM® (esomeprazole magnesium) Has Excellent Commercial Coverage


NEXIUM (esomeprazole magnesium) Commercial Coverage

The majority of patients with prescription drug coverage for NEXIUM pay $1 or less per day ¶#3

Individual out-of-pocket costs may vary.

Prevacid is a registered trademark of TAP Pharmaceuticals Products, Inc. Protonix is a registered trademark of Wyeth Pharmaceuticals Inc. Aciphex is a registered trademark of Eisai Company, Ltd. Fingertip Formulary is a registered trademark of Fingertip Formulary, LLC. Kapidex is a trademark of Takeda Pharmaceuticals North America, Inc., and is used under license by Takeda Pharmaceuticals America, Inc. Express Scripts is a registered trademark of Express Scripts, Inc. Preferred Prescriptions is a registered trademark and Rx Selections is a trademark of Medco Health Solutions, Inc.

Details

*Individual plans may vary.

†Wolters Kluwer Health, Dynamic Claims, January - March 2009. Database included over 1 million NEXIUM pharmacy benefit claims during the 1st quarter of 2009 (last accessed May 11, 2009).

#Individual out-of-pocket costs may vary. Based on monthly out-of-pocket retail pharmacy costs for Commercial Insurance and Medicare Part D Standard Eligible patients. Excluding claims from Medicare Part D Low Income Subsidy and Dual Eligibles, Cash (uninsured), and Medicaid, the percentage of beneficiaries paying $30 or less per month in out-of-pocket costs ranged from 55.97% to 65.85% during the most recent twelve-month period. Data included claims covering 4,100 plans.

Accessibility of NEXIUM

Search by state to find plan coverage for NEXIUM in your area.

Get started now

Patient Support

Help patients get the most from their prescribed treatment through the Purple Plus™ Program.

Learn more

Sign Up

Receive updates and offers from the maker of NEXIUM.

Register Now


Approved Uses

Healing of Erosive Esophagitis (EE)

NEXIUM 40 mg and NEXIUM 20 mg are indicated for short-term treatment (4 to 8 weeks) in healing and symptomatic resolution of diagnostically confirmed EE.

Maintenance of Healing of EE

NEXIUM 20 mg is indicated to maintain symptom resolution and healing of EE. Controlled studies did not extend beyond 6 months.

Symptomatic GERD

NEXIUM 20 mg is indicated for the treatment of heartburn and other symptoms associated with GERD.

Pediatric Use

NEXIUM is indicated for the short-term treatment (up to 8 weeks) of GERD (symptomatic GERD and healing of EE) in patients 1 to 17 years of age. Pediatric use is supported by extrapolation of results from studies that supported the approval for NEXIUM for adults and safety and pharmacokinetic studies performed in pediatric and adolescent patients.

Effectiveness has not been demonstrated in patients less than 1 year of age. Safety and effectiveness for other pediatric uses have not been established.

Important Safety Information

Please click here for the full Prescribing Information pdf (PDF – 303 KB) for NEXIUM.

Please see the full Prescribing Information available at the Web site for NEXIUM.

References
  1. Data on file, eSTaR# 269188: Fingertip Formulary, July 9, 2009.
  2. Data on file, eSTaR# 268197: Wolters Kluwer Health, Dynamic Claims, January - March 2009 (last accessed May 11, 2009).
  3. Data on file, eSTaR #271299: Wolters Kluwer Health, Dynamic Claims, April 2008 - March 2009 (last accessed May 13, 2009).